News · 26 weeks51-37%
2026-03-012026-08-23
Mix3190d
- Other12(39%)
- Insider10(32%)
- SEC Filings9(29%)
Latest news
25 items- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic InnovationU.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has advanced wi
- SECAmendment: SEC Form F-3/A filed by SciSparc Ltd.F-3/A - SciSparc Ltd. (0001611746) (Filer)
- SECAmendment: SEC Form 20-F/A filed by SciSparc Ltd.20-F/A - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 MillionSciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financing TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million. SciSparc participated in the financing with a C$2.7 million investment, representing 50% of the total gross proceeds r
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic CombinationTEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols." The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette SyndromeTEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced the initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome ("TS") in adults. The trial is now progressing at the Yale Child Study Center,
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data AnalyticsTEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics (the "Platform"). The Platform has successfully demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework, from secure data ingestion and preparation, through
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 companyTEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the "Platform"). The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum-clas
- PRSciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and CybersecurityTEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its board of directors has made a decision to target the agentic artificial intelligence ("AI") market. As part of this initiative, the Company has decided to establish a Scientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field. About SciSparc Ltd. (NASDAQ:SPRC): The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeTEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany ("MHH"), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing
- INSIDERAmendment: New insider Adler Oz claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Revach Moshe claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Shay Amnon Ben claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Sidi Liat claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Dayan Alon claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Weiss Amitay claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Vider Lior claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Shrem Itschak claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
SPRC FAQ
5 questionsWhat does SciSparc Ltd. do?
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health...Where does SPRC stock trade?
SciSparc Ltd. (SPRC) is listed on NASDAQ.What sector and industry is SPRC in?
SciSparc Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SPRC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRC side-by-side with any of them on Quantisnow.How can I track SPRC on Quantisnow?
Quantisnow aggregates SciSparc Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRC to receive live email and push alerts on every new disclosure.